CY1121345T1 - Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης - Google Patents

Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης

Info

Publication number
CY1121345T1
CY1121345T1 CY20191100279T CY191100279T CY1121345T1 CY 1121345 T1 CY1121345 T1 CY 1121345T1 CY 20191100279 T CY20191100279 T CY 20191100279T CY 191100279 T CY191100279 T CY 191100279T CY 1121345 T1 CY1121345 T1 CY 1121345T1
Authority
CY
Cyprus
Prior art keywords
lysosomic
pharmaceutical compositions
storage disorders
addressed
uses addressed
Prior art date
Application number
CY20191100279T
Other languages
English (en)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of CY1121345T1 publication Critical patent/CY1121345T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα αποκάλυψη προβλέπει αγωγή διαταραχών λυσοσωμιακής αποθήκευσης (LSD) περιλαμβάνοντας χορήγηση ακετυλ-λευκίνης ή ενός φαρμακευτικώς αποδεκτού άλατος εξ αυτής.
CY20191100279T 2016-08-11 2019-03-08 Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης CY1121345T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
PCT/IB2017/054928 WO2018029657A1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders

Publications (1)

Publication Number Publication Date
CY1121345T1 true CY1121345T1 (el) 2020-05-29

Family

ID=59859423

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100279T CY1121345T1 (el) 2016-08-11 2019-03-08 Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CY20211100017T CY1123844T1 (el) 2016-08-11 2021-01-12 Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100017T CY1123844T1 (el) 2016-08-11 2021-01-12 Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης

Country Status (28)

Country Link
US (3) US11400067B2 (el)
EP (4) EP3359146B1 (el)
JP (3) JP7393943B2 (el)
KR (4) KR20240110078A (el)
CN (1) CN109843275A (el)
AU (2) AU2017308864B2 (el)
BR (1) BR112019002719A2 (el)
CA (1) CA3033557A1 (el)
CY (2) CY1121345T1 (el)
DK (2) DK3482754T3 (el)
ES (2) ES2849566T3 (el)
HK (1) HK1253282B (el)
HR (2) HRP20190344T1 (el)
HU (2) HUE052837T2 (el)
IL (2) IL314107A (el)
LT (2) LT3359146T (el)
MA (2) MA43876B1 (el)
MD (2) MD3482754T2 (el)
ME (1) ME03340B (el)
MX (2) MX2019001577A (el)
PL (2) PL3359146T3 (el)
PT (2) PT3482754T (el)
RS (2) RS61442B1 (el)
RU (2) RU2749515C2 (el)
SG (1) SG11201901048VA (el)
SI (2) SI3482754T1 (el)
TN (1) TN2019000032A1 (el)
WO (1) WO2018029657A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017308864B2 (en) * 2016-08-11 2023-06-01 Intrabio Limited Pharmaceutical compositions and uses directed to lysosomal storage disorders
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
MX2021006559A (es) * 2018-12-06 2021-08-16 Intrabio Ltd Analogos deuterados de acetil-leucina.
EP3934637B1 (en) 2019-03-02 2024-07-31 IntraBio Ltd (n-)acetyl-l-leucine for use in treating traumatic brain injury
EP3989962A1 (en) 2019-06-28 2022-05-04 IntraBio Ltd Combination therapy with acetyl-leucine and miglustat
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (en) * 2008-03-14 2009-09-17 Irm Llc Compounds, compositions and methods for treating lysosomal storage diseases and disorders
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
GB201114017D0 (en) * 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
CA2915127A1 (en) * 2012-06-06 2013-12-12 Giancarlo PARENTI Allosteric chaperones and uses thereof
AU2017308864B2 (en) * 2016-08-11 2023-06-01 Intrabio Limited Pharmaceutical compositions and uses directed to lysosomal storage disorders
CA3033564A1 (en) * 2016-08-11 2018-02-15 Intrabio Limited Acetyl-leucine for neurodegenerative diseases

Also Published As

Publication number Publication date
JP2019524821A (ja) 2019-09-05
PT3359146T (pt) 2019-03-27
AU2023202903A1 (en) 2023-05-25
PT3482754T (pt) 2021-02-03
RS61442B1 (sr) 2021-03-31
ME03340B (me) 2019-10-20
US20240197663A1 (en) 2024-06-20
DK3482754T3 (da) 2021-02-01
EP4342461A3 (en) 2024-05-29
RS58478B1 (sr) 2019-04-30
ES2849566T3 (es) 2021-08-19
HK1253282B (zh) 2020-02-07
IL264610A (en) 2019-02-28
WO2018029657A1 (en) 2018-02-15
CY1123844T1 (el) 2022-05-27
EP3865126A1 (en) 2021-08-18
RU2019106493A3 (el) 2020-10-26
JP2024059863A (ja) 2024-05-01
MX2021008432A (es) 2021-08-19
KR102412724B1 (ko) 2022-06-23
LT3482754T (lt) 2021-05-10
IL264610B1 (en) 2024-08-01
EP4342461A2 (en) 2024-03-27
TN2019000032A1 (en) 2020-07-15
EP3482754B1 (en) 2020-12-23
KR20220154849A (ko) 2022-11-22
RU2021115932A (ru) 2021-06-08
AU2017308864B2 (en) 2023-06-01
KR20220044372A (ko) 2022-04-07
KR20190039226A (ko) 2019-04-10
PL3482754T3 (pl) 2021-07-05
JP2022050564A (ja) 2022-03-30
EP3482754A1 (en) 2019-05-15
CN109843275A (zh) 2019-06-04
KR102467953B1 (ko) 2022-11-16
MA43876A (fr) 2018-08-15
LT3359146T (lt) 2019-04-25
RU2019106493A (ru) 2020-09-11
HUE052837T2 (hu) 2021-05-28
HRP20210153T1 (hr) 2021-05-28
MA55947A (fr) 2022-03-23
SI3359146T1 (sl) 2019-05-31
MX2019001577A (es) 2019-08-29
CA3033557A1 (en) 2018-02-15
BR112019002719A2 (pt) 2019-05-14
JP7393943B2 (ja) 2023-12-07
SG11201901048VA (en) 2019-03-28
HRP20190344T1 (hr) 2019-04-19
PL3359146T3 (pl) 2019-07-31
IL314107A (en) 2024-09-01
HK1253282A1 (zh) 2019-06-14
SI3482754T1 (sl) 2021-04-30
MD3359146T2 (ro) 2019-04-30
DK3359146T3 (en) 2019-04-08
ES2716133T3 (es) 2019-06-10
MA43876B1 (fr) 2019-04-30
HUE041914T2 (hu) 2019-06-28
RU2749515C2 (ru) 2021-06-11
MD3482754T2 (ro) 2021-05-31
US20190201359A1 (en) 2019-07-04
EP3359146B1 (en) 2019-01-23
KR20240110078A (ko) 2024-07-12
EP3359146A1 (en) 2018-08-15
US11400067B2 (en) 2022-08-02
US20220331278A1 (en) 2022-10-20
AU2017308864A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
EA201790785A1 (ru) Производные тетрагидроизохинолина
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CY1121930T1 (el) Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112017028140A2 (pt) formulações farmacêuticas
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CY1124967T1 (el) Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение